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BACKGROUND: Epoetin-b is used to treat patients with cancer undergoing chemotherapy to alleviate the symptoms of anaemia, reduce
the risk of blood transfusions and improve quality of life (QoL).
METHODS: This meta-analysis of all 12 randomised, controlled studies of epoetin-b evaluated the impact of therapy at different
Hb-initiation levels and to different target Hb levels on overall survival, tumour progression and thromboembolic events (TEE). An
analysis of risk factors pre-disposing patients to TEEs under epoetin-b therapy was also performed. A total of 2297 patients are
included in the analysis.
RESULTS: Analyses based on various Hb-initiation levels indicate no detrimental impact on survival (HR 0.99; 95% CI 0.70, 1.40) and a
favourable impact on disease progression (HR 0.73; 95% CI 0.57, 0.94) when epoetin-b was used within its licensed indication
(Hb initiation p10gdl
 1) or the EORTC recommended level of 11gdl
 1. An increased risk of TEEs is seen for all Hb-initiation level
strata and a detrimental impact on survival is seen when initiating epoetin-b therapy at Hb levels 411gdl
 1. We observe no
association between high target Hb levels (X13gdl
 1) and an increased risk of mortality, disease progression or TEEs with epoetin-b
compared with control.
CONCLUSION: The results of this analysis indicate that epoetin-b therapy has no detrimental impact on survival or tumour progression
when initiated at Hb levels up to 11gdl
 1. Furthermore, there is no evidence to suggest that high Hb values achieved during epoetin-b
therapy are associated with an increased mortality, disease progression or TEE rate.
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Anaemia frequently occurs in patients with cancer either as a result
of the underlying malignancy or as a consequence of myelo-
suppressive chemotherapy or radiotherapy, or due to a combination
of both (Bokemeyer et al, 2005). The symptoms of anaemia have a
significant impact on a patient’s condition and QoL (Ludwig et al,
2004) and as an independent prognostic factor, anaemia is
associated with adverse outcomes in patients with a variety of
malignancies (Caro et al, 2001).
Erythropoiesis-stimulating agents (ESAs) increase Hb levels and
reduce transfusion requirements in patients with cancer (Little-
wood et al, 2001; O ¨sterborg et al, 2002; Vansteenkiste et al, 2002).
In addition, improvement in patients’ QoL when compared with
placebo or standard transfusion therapy was also shown following
ESA therapy (Littlewood et al, 2001; Crawford et al, 2002;
Boogaerts et al, 2003).
Pre-clinical data have suggested an enhanced tumour response
and delayed tumour progression associated with ESA treatment
(Mittelman et al, 2001; Thews et al, 2001; Stuben et al, 2003).
Moreover, in clinical studies, a potential survival benefit has been
shown in patients undergoing cancer therapy who received
treatment with ESAs (Antonadou et al, 2001; Glaser et al, 2001;
Littlewood et al, 2001). The first of two meta-analyses of controlled
trials in cancer patients receiving ESAs, reported by the Cochrane
Group, showed a trend toward increased survival in patients
treated with ESAs and supported these findings (Bohlius et al,
2005). In the second meta-analysis (57 trials including 9353
patients), however, a shift of the hazard ratio for survival towards
an increased risk for patients receiving various ESAs was shown
(Bohlius et al, 2006, 2008).
An association between erythropoietin treatment and increased
mortality was originally suggested by two studies in cancer
patients (Henke et al, 2003; Leyland-Jones et al, 2005) raising
concerns about the safety of ESAs when targeting high Hb levels
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s(12–14gdl
 1 or higher) (Luksenburg et al, 2004). In addition,
three studies reporting a detrimental impact of ESA treatment on
survival have recently been published (Overgaard et al, 2007;
Wright et al, 2007; Smith et al, 2008), although one of these
studies (Overgaard et al, 2007) remains to be reported in full.
Methodological limitations of the clinical studies aimed at
maintaining a high Hb level in cancer patients (Henke et al,
2003; Leyland-Jones et al, 2005), may have confounded the results
and influenced the findings (Leyland-Jones and Mahmud, 2004;
Vaupel and Mayer, 2004). Studies evaluating different haematocrit
levels in end-stage renal failure patients with cardiovascular risk
factors (Besarab et al, 1998; Luksenburg et al, 2004) have suggested
that increased mortality may be because of a higher risk of
thromboembolic events (TEEs) under ESA therapy. Hypotheses
that ESAs may promote tumour growth through erythropoietin
receptor activation, stimulation of angiogenesis or through
hypoxia improvement through Hb increases have also been
proposed (Kelleher et al, 1998; Acs et al, 2001, 2002; Arcasoy
et al, 2002; Yasuda et al, 2003; Janecka, 2004; Vaupel and Mayer,
2004).
We previously reported results of an updated meta-analysis of
12 randomised, controlled studies of epoetin-b conducted in 2301
patients undergoing cancer therapy (Aapro et al, 2008a) including
three recently completed trials with longer term follow-up in
patients with head and neck cancer (Henke et al, 2003), patients
with metastatic breast cancer (Aapro et al, 2008b) and patients
with cervical cancer (Strauss et al, 2008). The results of this meta-
analysis based on individual patient level data showed no
statistically significant difference between patients receiving
epoetin-b or control (standard treatment) in terms of overall
survival, a favourable trend with respect to the risk of disease
progression for patients receiving epoetin-b and a higher risk of
thromboembolic events associated with epoetin-b treatment
(Aapro et al, 2008a). Recently, the Cochrane Collaboration has
published an updated meta-analysis, which includes data on
epoetin-a, epoetin-b and darbepoetin from 53 randomized,
controlled studies in cancer patients. The data from this updated
meta analysis, suggested a negative effect on overall survival in the
overall study population, however, in those patients receiving
cancer chemotherapy, no significant adverse effects on overall
survival were observed (Bohlius et al, 2009).
As a consequence of the safety concerns raised by some studies,
the European Health Authorities requested the product labels for
marketed ESAs to be restricted to a Hb-initiation level o10gdl
 1
and a Hb target not to exceed 12gdl
 1. Furthermore, the European
Health Authorities have stated that transfusions should be seen as
the preferred option. The updated EORTC treatment guidelines,
however, recommend the initiation of ESA therapy at Hb levels of
between 9 and 11gdl
 1 and a sustained Hb level of B12gdl
 1
should be the target for treatment with ESAs (Bokemeyer et al,
2007; Aapro and Link, 2008). Below a Hb level of 9gdl
 1, blood
transfusions followed by ESA treatment should be considered and
prophylactic use of erythropoietins in subjects with normal Hb
levels scheduled to undergo chemotherapy or radiotherapy is not
recommended.
The objectives of this analysis are to evaluate the impact on
overall survival, disease progression and TEEs of different Hb
intervention and target levels for epoetin-b therapy and in
particular, to explore the safety of epoetin-b with respect to its
effects on overall survival and disease progressions when used
within the Hb intervention and target levels as recommended in
the revised European label. These data have not been reported
as yet and are considered of considerable relevance for prescribing
physicians. Furthermore, the influence of baseline prognostic
factors on the observed epoetin-b effect with respect to time to
thromboembolic event in the pooled patient population (N¼2301)
from 12 controlled epoetin-b trials in cancer patients was
assessed.
MATERIALS AND METHODS
Data presented in this article are derived from an updated meta-
analysis of 12 controlled studies designed to evaluate differences
between epoetin-b and control (placebo or standard care) with
regard to overall survival, disease progression and TEEs during
and up to 28 days after end of therapy with epoetin-b.
Eligible studies included all randomised, controlled studies of
epoetin-b conducted by the drug sponsor (F Hoffmann-La Roche
(Basel, Switzerland) or Boehringer Mannheim) in patients with cancer
undergoing treatment (chemotherapy (seven studies), surgery (two
studies), radiotherapy (two studies) or radio-chemotherapy (1 study)).
The meta-analysis is based on data derived at the individual patient
level. Individual study details are summarised in Table 1.
As most of the studies were originally designed to evaluate the
efficacy of epoetin-b with respect to anaemia correction, in the
majority there was no follow-up for survival or tumour progres-
sion beyond study treatment plus a standard 28-day period used to
assess SAEs, deaths and disease progression. Furthermore, tumour
status was not prospectively assessed in many of the earlier trials
with short-term follow-up and details of disease progression were
routinely reported as adverse events. For the meta-analysis, this
information was analysed retrospectively by reviewers blinded to
treatment assignment. Four of the studies, which did evaluate the
effects of epoetin-b on survival and/or disease progression (Henke
et al, 2003; O ¨sterborg et al, 2005; Aapro et al, 2008b) or response to
treatment (Strauss et al, 2008) provided long-term (up to 60
months) follow-up information for overall survival or tumour
progression. For the assessment of TEEs, all reported adverse
events were reviewed against a pre-specified list of TEEs, which
was applied consistently across all studies.
Statistical analyses
Overall survival, time to progression and time to TEE were
analysed by Kaplan–Meier estimates in which the data were
stratified; (1) by Hb intervention level (baseline Hb level), and (2)
by maximum Hb level achieved up to 28 days after end of
treatment (target Hb level).
Two sets of analyses were performed. One set of analyses
included individual patient data from all 12 studies. For these
analyses, patients without events were censored at 4 weeks after the
last entry in the administration record. A second set of analyses
using only pooled patient data from the studies with long-term
follow up in which all events were included in the analysis was
performed for overall survival (Henke et al, 2003; O ¨sterborg et al,
2005; Strauss et al, 2008; Aapro et al, 2008b) and time to
progression (Henke et al, 2003; Strauss et al, 2008; Aapro et al,
2008b). In the study by O ¨sterborg et al, 2005, patients were
followed for survival but not for disease progression, therefore this
study was excluded from the time to progression analyses. Patients
without an event were censored at the time of last follow-up or, if
no follow-up information was available, 4 weeks after the last entry
in the administration record. Overall analyses were performed,
unstratified as well as stratified by the study.
Risk factors for TEEs and their influence on the observed
epoetin treatment effect were also investigated. Potential risk
factors were defined at baseline and, as a first step, univariate
models estimated the effect of the prognostic factor as well as a
corrected treatment effect. Factors that were statistically significant
in the univariate model or showed a trend at an a-level of 15%
were then selected and patients classified into risk subgroups
based on clinically established risk profiles. The impact of these
selected factors on time to TEE was then analyzed in Cox
regression models adjusting by subgroup for each factor
separately, for subgroups of patients with no risk factors, one,
two and three or more risk factors at baseline to investigate
whether a potential risk for TEE in combination with epoetin-b
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streatment was attributable to a particular subgroup of patients at
specific risk.
RESULTS
Analysis populations
The 12 randomized, controlled trials enrolled a total of 2301
patients of whom 2297 (epoetin-b, n¼1244; control, n¼1053)
were included in the analysis; four patients were excluded because
of not receiving treatment of any kind during the trials. In the
studies, three patients in the epoetin group received no epoetin-b
and five patients randomised to control received epoetin-b.
Patients were analysed according to the treatment received.
Baseline characteristics and follow-up
Baseline characteristics of the patients in the analysis are described
in the earlier publication (Aapro et al, 2008a) and are shown in
Table 2. Of the 2297 patients in the analysis, 35% had non-myeloid
haematological malignancies (mainly non-Hodgkin’s lymphoma or
multiple myeloma) and 65% had solid tumours (most commonly
primary malignancies of the breast, head and neck, colon/rectum
and ovary). Other than the slightly higher proportion of patients in
the epoetin group with ovarian carcinoma as a result of the three
arm design of the study by ten Bokkel Huinink et al (1998), no
clinically relevant differences between the groups were noted.
Median initial weekly epoetin-b dose was 27000IU (range
0–90000IU). Mean baseline Hb level was 10.6gdl
 1 in the control
arm and 10.5gdl
 1 in the epoetin-b arm. During treatment, mean
maximum Hb level was 13.4gdl
 1 in the epoetin-b arm and
12.0gdl
 1 in the control arm. The mean baseline adjusted Hb area
under the curve was 1.24gdl
 1 with epoetin-b compared with
0.07gdl
 1 with control.
Duration of follow up across the 12 studies was comparable in
the epoetin-b (median 3.9 months) and control (median 3.8
months) treatment groups (patients without events from the four
studies with long-term follow up were censored 4 weeks after last
entry in the administration record). In the four studies with long-
term follow-up data, when all events were included, median follow
up was also comparable (28.8 months with epoetin-b and 29.8
months with control) (Aapro et al, 2008a).
Impact of baseline Hb level on overall survival
As previously described in Aapro et al (2008a), there was no
statistically significant difference between patients receiving
epoetin-b or control (standard treatment) in terms of overall
survival in the unstratified pooled analysis of all 12 controlled
studies (HR of 1.13, 95% CI 0.87; 1.46, log-rank P-value¼0.355,
N¼2297). Comparable results were found in the unstratified
pooled analysis of the four studies with long-term follow up (HR of
1.13 (95% CI 0.98; 1.31, log-rank P-value¼0.082, N¼1227).
When stratified by baseline Hb level, the time to event analyses
in patients with baseline Hb levels p10gdl
 1 showed a HR of 0.99
(95% CI 0.70; 1.40; log-rank P-value¼0.96; N¼950) (Figures 1A
and 2A) and for patients with baseline Hb levels p11gdl
 1 aH R
of 1.09 (95% CI 0.80; 1.47; N¼1426) (Figure 2A). These results are
within the range of those for the unstratified pooled population.
However, for patients whose baseline Hb levels were above
11gdl
 1, the mortality risk appeared to be higher (HR of 1.25,
95% CI 0.75; 2.07; N¼865) (Figure 2A).
Comparable results were found in the pooled analysis of four
studies with long-term follow up (Table 3). These data suggest no
increased risk of epoetin-b treatment on overall survival in
Table 1 Main features of randomised clinical trials of epoetin-b in patients with cancer
Study
Design and no.
of patients
(epoetin-b/ control) Diagnosis
Epoetin-b dosage and
duration of therapy Control
Cancer
treatment
ten Bokkel Huinink
et al (1998)
o, pg n¼83/87 Ovarian cancer, Hb o13gdl
 1 150 or 300IUkg
 1 3 week
 6 months
Standard therapy Chemotherapy
O ¨ sterborg et al
(1996)
o, pg n¼95/49 MM, NHL, CLL; transfusion-dependent,
Hb o10gdl
 1
2000–10000IUday
 1 titrated or
10000IUday
 1 fixed
dosage 24 weeks
Standard therapy Chemotherapy
Rau et al (1998) db, pc and pg
n¼28/26
Resectable rectal cancer, Hb X
12.5gdl
 1 (men), X12gdl
 1 (women)
200IUkg
 1 daily 11 days Placebo Surgery
Kettelhack et al
(1998)
db, pc n¼52/57 Colorectal cancer suitable for
hemicolectomy, Hb 48.5–13.5gdl
 1
20000IUday
 1 10–15 days Placebo Surgery
Data on file (study
MF4266)
o, pg n¼10/10 AML 10000IUday
 1, then weekly or
twice weekly  p30 weeks
Standard therapy Chemotherapy
Cazzola et al
(1995)
o, pg n¼117/29 MM, NHL, CLL; transfusion-independent,
Hbp11gdl
 1
1000, 2000, 5000 or
10000IUday
 1 8 weeks
Standard therapy Chemotherapy
Oberhoff et al
(1998)
pg, n¼114/104 Solid organ tumours, Hbp11gdl
 1 5000IUday
 1 12–24 weeks Standard therapy Chemotherapy
Boogaerts et al
(2003
o, pg n¼131/128 Malignant disease, Hbp11gdl
 1 150IUkg
 1 3 week adjusted
for Hb response 12 weeks
Standard therapy Chemotherapy
O ¨ sterborg et al
(2002, 2005)
pc, db and pg
n¼170/173
MM, NHL, CLL; transfusion-dependent
and epo-deficient, Hbp10gdl
 1
150IUkg
 1 3 week adjusted
for Hb response 16 weeks
12-month study period
a
Placebo Chemotherapy
Henke et al
(2003)
pc, db and pg
n¼171/180
Head and neck cancer, Hbo13gdl
 1
(men), o12gdl
 1 (women)
300IUkg
 1 3 week, 6–8
weeks 60-month study period
Placebo Radiotherapy
Strauss et al
(2008)
o, pg n¼34/40 Cervical cancer Stage FIGO IIB-IVA,
Hb 9–13gdl
 1
150IUkg
 1 3 week, 8–14
weeks, 6-month study period
Standard therapy Radio-
chemotherapy
Aapro et al
(2008b)
o, pg n¼231/232 Breast cancer, Hbo12.9gdl
 1 30000IU weekly 24 weeks,
24-month study period
Standard therapy Chemotherapy
Abbreviations: AML¼acute myeloid leukaemia; CLL¼chronic lymphocytic leukaemia; db¼double-blind; Hb¼haemoglobin; MM¼multiple myeloma; NHL¼non-Hodgkin’s
lymphoma; o¼open design; pc¼placebo controlled; pg¼parallel group. Patients had anaemia unless stated otherwise, and standard therapy consisted of antitumour treatment
plus blood transfusion as required. Reproduced from Aapro et al, 2008a.
aInformation on disease progression not collected during the follow-up period of this study.
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spatients whose baseline haemoglobin was p10gdl
 1 (HR¼0.91,
95% CI 0.72; 1.16) or p11gdl
 1 (HR¼1.03, 95% CI 0.85; 1.25),
which was consistent with the unstratified analysis (HR¼1.13,
95% CI 0.98; 1.31, log-rank P-value¼0.082). In patients whose
baseline haemoglobin levels were above 11gdl
 1, however, the risk
of mortality appeared to increase (HR¼1.24, 95% CI 1.00; 1.53).
Impact of baseline Hb levels on disease progression
In the unstratified pooled analysis of 12 controlled studies, no
significant differences between the epoetin-b and control groups
were seen in the number of patients with disease progression
(Aapro et al, 2008a). Kaplan–Meier analysis indicated a reduced
risk of progression for patients treated with epoetin b compared
with control (HR¼0.85, 95% CI 0.72; 1.01, log-rank
P-value¼0.072).
When stratified by baseline Hb level, the subgroup with a
baseline Hb level p10gdl
 1 had a relative risk reduction for
disease progression of 27% (HR 0.73, 95% CI 0.57; 0.94; log-rank
P-value¼0.013; N¼950) (Figures 1B and 2B) and the subgroup
with a baseline Hb level p11gdl
 1 had a relative risk reduction
for disease progression of 20.0% (HR 0.80, 95% CI 0.65; 0.99;
N¼1426) with epoetin-b compared with control (Figure 2B).
These results are consistent with the results for the pooled
population (relative risk reduction of 15%). For patients with
baseline Hb values 411gdl
 1, there was no evidence of an
increased risk of disease progression associated with epoetin-b
treatment (HR 0.95, 95% CI 0.70; 1.28) (Figure 2B).
In the three studies with long-term follow up of disease
progression, results suggested favourable effects of epoetin-b over
control with respect to disease progression in the subgroups with a
baseline Hb level p10gdl
 1 (HR¼0.59, 95% CI 0.36; 0.96) and a
baseline Hb level p11gdl
 1 (HR¼0.85, 95% CI 0.64; 1.13;
Table 3). This finding contrasts with a 13% higher risk of disease
progression for the unstratified pooled population. For subgroups
with baseline Hb levels 411dl
 1, the relative risk for disease
progression with epoetin-b increased by 30% compared with
control (Table 3).
Impact of baseline Hb levels on time to TEE
Across the 12 studies in the unstratified pooled analysis, a higher
TEE event rate was observed in the epoetin-b group compared
with the control (0.22 vs 0.14 events/patient year) with an overall
HR for time to TEE of 1.62 (95% CI 1.13; 2.31, log-rank
P-value¼0.008) (Aapro et al, 2008a).
When stratified by baseline Hb level (Figure 2C) an increased
risk of thromboembolic events with epoetin-b compared with
control was seen across all baseline Hb strata subgroups; the risk
being lowest in patients with baseline Hb levels p10gdl
 1 and
increasing with the higher the baseline Hb level.
Impact of maximum-achieved Hb levels on survival,
disease progression and TEEs
The hazard ratios for overall survival, time to progression and time
to TEE stratified by maximum-achieved Hb level for the pooled
population of 12 studies are shown in Figure 3. These data indicate
a shift towards an increased mortality risk for subgroups with
maximum-achieved Hb values between 10 and o13gdl
 1 (HR
range: 1.20–2.60 for overall survival (Figure 3A); 1.11–1.45 for
disease progression (Figure 3B); 1.53–5.04 for time to TEE
(Figure 3C)). However, there was no indication for an increased
risk of mortality, disease progression or TEEs in patients achieving
maximum Hb levels 413gdl
 1 (HR¼0.79, 1.08 and 1.32,
respectively) when compared with the unstratified analyses
(Figure 3).
In the pooled analyses of studies with long-term follow up
(Table 3), a shift of the hazard ratio towards an increased mortality
risk was seen for subgroups with maximum-achieved Hb values
between 10 and o12gdl
 1 (HR range 1.71–1.89 for overall
survival). However, for subgroups with maximum-achieved Hb
levels X12gdl
 1 (HR range 1.50–1.59) there was no indication for
a further increased risk of mortality.
With regards to disease progression in the three studies with
long-term follow up, a shift in the hazard ratios towards an
increased risk of progression was seen in all subgroups with
maximum-achieved Hb values of between 10 and p13gdl
 1.
However, there was no indication of an increased risk in the
subgroup of patients achieving maximum Hb levels 413gdl
 1
(Table 3).
Risk factors for thromboembolic events
Risk factors and their influence on the epoetin-b treatment effect
with respect to TEEs were investigated in a Cox regression model
into which treatment and other prognostic factors were added
(Table 4). Five factors; previous history of TEEs, previous coronary
artery disease, baseline hypertension, baseline dyslipidemia and
age at baseline 465 years were statistically significant or showed a
trend at an a-level of 15% in these univariate models. Adjusted
treatment effects remained unchanged. Results of the Cox
regression analysis based on the number of risk factors at baseline
indicated that the risk of TEEs was generally higher in patients
with two or more risk factors compared to those with fewer than
two risk factors; Table 4). Overall analyses stratified by study
yielded similar results.
Table 2 Baseline characteristics of pooled study populations
Parameter
Control
(n¼1053)
Epoetin-b
(n¼1244)
Gender (Percentage of male/female) 37/63 38/62
Race
n 921 1069
Caucasian 882 (96%) 1029 (96%)
Other 39 (4%) 40 (4%)
Mean age in years (range) 58.8 (19–91) 59.3 (20–87)
Mean weight in kg (range) 67.7 (30.0–131.5) 67.1 (35.0–118.0)
n 1048 1235
Mean height in cm (range) 166.7 (140–198) 166.4 (126–198)
n 809 1012
Tumour type, n (%)
Haematological 331 (31.4) 465 (37.4)
Acute myeloid leukaemia 10 (3.0) 10 (2.2)
Multiple myeloma 125 (37.8) 204 (43.9)
Non-Hodgkin’s lymphoma 195 (58.9) 247 (53.1)
Hodgkin’s lymphoma 1 (o1) 4 (o1)
Solid 722 (68.6) 779 (62.6)
Breast 261 (36.2) 261 (33.5)
Head/neck 174 (24.1) 181 (23.2)
Gynaecological 133 (18.4) 186 (23.9)
Gastrointestinal 96 (13.3) 100 (12.8)
Other 58 (8.0) 51 (6.6)
Haemoglobin
n 1050 1241
Mean (range) 10.6 (5.7–16.7) 10.5 (4.2–17.1)
Median 10.5 10.4
Data were collected from all 2297 patients unless otherwise stated. Reproduced from
Aapro et al, 2008a.
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sDISCUSSION
Impact of baseline Hb level
We reported previously that in an unstratified overall analysis,
patients in the epoetin-b group had a numerically, but statistically
non-significant increased risk of mortality compared with patients
in the control group (Aapro et al, 2008a). These results are
consistent both with those of a recently published, individual
patient data-based meta-analysis by the Cochrane Collaboration
(Bohlius et al, 2009), which showed no negative effect of epoetin
therapy in patients receiving chemotherapy, and with those from a
subset of patients receiving chemotherapy in a meta-analysis
published by Tonelli et al (2009). In contrast to our results,
however, in the overall study population of the meta-analysis
published by the Cochrane Collaboration, which included patients
not receiving chemotherapy, a detrimental effect on overall
survival was observed.
When stratified by baseline Hb level, no significantly increased
negative effects on mortality were seen for the epoetin-b group up
to a baseline Hb level of 11gdl
 1. Above this baseline Hb level, the
risk of mortality increased for epoetin-b patients compared with
control patients. The robustness of these findings was confirmed in
the pooled analyses of four studies, which collected long-term
follow-up survival data (1227 patients) in which an increased risk
of mortality was only seen in the subgroup of patients initiating
epoetin-b therapy with a baseline Hb 411gdl
 1.
These results support the current labelling for epoetin-b, which
recommends a Hb-initiation level of p10gdl
 1 and the updated
EORTC treatment guidelines (Bokemeyer et al, 2007; Aapro and
Link, 2008), which recommend a Hb-initiation level of p11gdl
 1.
Comparable results have been reported by the Cochrane Group
from an aggregated study data-based meta-analysis of ESA studies
(Bohlius et al, 2006), where no significantly increased risk of
mortality was seen between the ESA and control groups in those
studies, which enrolled patients with baseline Hb levels o10gdl
 1
or in studies enrolling patients with baseline Hb levels
10–12gdl
 1. However, in studies enrolling patients with baseline
Hb levels above this level (7 trials; 1696 patients) an increased risk
of death was seen in the ESA group.
A favourable outcome with respect to disease progression with
ESAs vs control was previously shown by the Cochrane
Collaboration (Bohlius et al, 2006), and in a systematic review of
46 ESA trials conducted for the National Institute for Clinical
Excellence (NICE) (Wilson et al, 2007). Consistent with these
findings, in this analysis, epoetin-b treatment showed a reduced
risk of disease progression both in the overall unstratified analysis
and when restricted to three studies with long-term follow up for
disease progression (N¼884). Analyses of the overall pooled
population stratified by baseline Hb level showed similar
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Figure 1 Kaplan–Meier time to event analyses of (A) overall survival and (B) time to progression in patients with Hb-initiation levels p10gdl
 1.
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1426
865 0.75 1.25 2.07
0.80 1.09 1.47
0.70 0.99 1.40
0.87 1.13 1.46
Lower
confidence
limit Estimate
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950
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865 0.70 0.95 1.28
0.65 0.80 0.99
0.57 0.73 0.94
0.72 0.85 1.01
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confidence
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confidence
limit
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950
1426
865 0.96 1.68 2.91
1.00 1.60 2.55
0.59 1.01 1.73
1.13 1.62 2.31
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confidence
limit Estimate
Upper
confidence
limit
Baseline Hb < 10 g dl–1
< 11 g dl–1
> 11 g dl–1
Category Subgroup
All All
Baseline Hb < 10 g dl–1
< 11 g dl–1
> 11 g dl–1
Category Subgroup
All All
Baseline Hb < 10 g dl–1
< 11 g dl–1
> 11 g dl–1
0.2 0.4 0.6 1 2 3 4561 0 2 0
Risk ratio
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Risk ratio
0.2 0.4 0.6 1 2 3 45 6 10 20
Risk ratio
Figure 2 Subgroup analysis of hazard ratios for (A) overall survival, (B) time to progression and (C) time to TEE by Hb-initiation level.
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sfavourable effects of epoetin-b vs control on disease progression in
subgroups with a baseline Hb level of p10gdl
 1, thus supporting
the current label, and subgroups with a baseline Hb level
p11gdl
 1, consistent with current EORTC guidelines (Aapro
and Link, 2008). In the stratified pooled analyses of the long-term
follow-up studies, the favourable effect on disease progression was
maintained for all subgroups, including those with baseline Hb
levels 411gdl
 1. These results suggest, therefore, that when
epoetin-b therapy is used according to its current label and
following the updated EORTC guidelines there is no increased risk
of disease progression vs control.
Impact of maximum-achieved Hb level
The increased mortality associated with erythropoietin treatment
in cancer patients reported by Henke et al (2003); Leyland-Jones
et al (2005), and more recently in studies by Overgaard et al
(2007); Wright et al (2007); Smith et al (2008), is not supported by
the present meta-analysis. Subgroup analyses based on maximum-
achieved Hb level during epoetin-b treatment do not provide
evidence for an increased risk of mortality, disease progression or
TEEs with epoetin-b compared with control in patients achieving
Hb levels 413gdl
 1, although we observe a shift in the hazard
ratios towards an increased risk for all three events associated with
maximum-achieved Hb values between 10 and 13gdl
 1.
The results of these analyses need to be interpreted with caution
because of the associated methodological limitations and potential
confounding influence of factors such as baseline disease status,
that are related to outcome and have a strong influence on the
likelihood of achieving a better response to treatment in terms of
Hb increase. Furthermore, the comparisons undertaken here were
not based on randomized groups and hence comparisons in each
of the subgroups are limited by the lack of a respective control. For
example, for the subgroup of patients with maximum-achieved Hb
levels o10gdl
 1, comparisons are made between patients receiv-
ing epoetin-b who, despite treatment, did not respond to therapy
and patients in the control group who remained below 10gdl
 1
without treatment. In contrast, in the subgroup of patients with
maximum-achieved Hb levels 413gdl
 1, the comparison is
between those patients who were titrated to beyond 13gdl
 1 with
epoetin-b therapy and those who either achieved Hb levels above
13gdl
 1 without treatment or who were enrolled with baseline Hb
levels above 13gdl
 1. On the assumption that an increase in Hb
levels independent of epoetin-b treatment is a good prognostic
factor, these analyses would therefore be biased in favour of the
control group. Nonetheless, no convincing evidence was found in
the present analyses to suggest that high Hb values achieved with
epoetin-b therapy are associated with an increased risk of death,
disease progression or TEEs.
Risk factors for thromboembolic events
The present analyses show a significantly increased TEE rate with
epoetin-b compared with control (0.22 events/patient year vs 0.14
events/patient year) and an increased risk of thromboembolic
events with epoetin-b. These results are consistent with those
reported in both meta-analyses of the Cochrane Collaboration
(Bohlius et al, 2005, 2006). Subgroup analyses based on Hb-
initiation level indicate a correlation between Hb-initiation level
and risk of TEE. This increased TEE risk is well documented within
the ESA class in general and adequately addressed in the product
labelling for all approved ESAs.
Among the multiple risk factors shown for thromboembolic
disease, the most influential include increasing age, prolonged
immobility, malignant disease, major surgery, multiple trauma,
previous venous thromboembolism and chronic heart failure
(Anderson and Spencer, 2003). Increased TEE risk has been
suggested to be related not only to the presence of these individual
risk factors, but also to the number of pre-disposing risk factors at
baseline (Nicolaides and Irving 1975; Wheeler et al, 1982). In the
present analysis five major pre-disposing risk factors for TEEs in
patients receiving epoetin-b therapy were identified (age 465
years, previous thromboembolic event, coronary artery disease,
hypertension and dyslipidemia). Furthermore, the combination of
two or more of these risk factors in epoetin-b-treated patients
markedly increased the risk of a TEE. Recently, an association
between RBC and platelet transfusions and an increased risk of
TEEs and mortality in cancer patients has also been suggested
(Khorana et al, 2008). Further investigation of this potential causal
relationship in patients included in the epoetin-b studies is
merited.
The results could suggest a potential role for the use of
prophylactic antithrombotic agents in patients with known risk
factors who are scheduled to receive epoetin-b therapy (Aapro
et al, 2009). Further investigation is required to confirm the
benefits of such treatment in combination with epoetin-b. These
results concerning the increased risk for TEEs with epoetin-b are
consistent with the observation and conclusions of the Cochrane
meta-analyses (Bohlius et al, 2005, 2006) and are currently
addressed in the labelling recommendations for epoetin-b.
Table 3 Hazard ratios for overall survival, time to progression and TEE by Hb-initiation level or maximum-achieved Hb level in long-term follow-up
studies
Overall survival Time to progression
Patient subgroup
Hb-initiation level
Number
of patients
Hazard ratio
(95% CI) P-value
a
Number
of patients
Hazard ratio
(95% CI) P-value
a
Long-term follow-up studies
All patients 1227 1.13 (0.98; 1.31) 0.082 884 1.13 (0.95; 1.34) 0.165
p10gdl
 1 393 0.91 (0.72; 1.16) 114 0.59 (0.36; 0.96)
p11gdl
 1 612 1.03 (0.85; 1.25) 285 0.85 (0.64; 1.13)
411gdl
 1 611 1.24 (1.00; 1.53) 595 1.30 (1.05; 1.61)
Maximum Hb value
Long-term follow-up studies
All patients 1227 1.13 (0.98; 1.31) 0.082 884 1.13 (0.95; 1.34) 0.165
o10gdl
 1 64 1.71 (0.97; 3.02) 16 10.17 (0.99; 104.36)
10–o11gdl
 1 163 2.09 (1.42; 3.08) 60 2.37 (1.01; 5.57)
11–o12gdl
 1 352 1.89 (1.45; 2.46) 166 1.85 (1.14; 2.98)
12–13gdl
 1 259 1.59 (1.15; 2.23) 191 1.75 (1.13; 2.69)
413gdl
 1 599 1.50 (1.16; 1.94) 511 1.83 (1.39; 2.41)
aHR P-value (Wald test).
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No. of
patients
No. of
patients
No. of
patients
2297
230
506
870
426
951 0.41 0.79 1.51
1.22 2.60 5.53
1.36 1.89 2.63
1.15 1.73 2.61
0.70 1.20 2.05
0.87 1.13 1.46
Lower
confidence
limit Estimate
Upper
confidence
limit
2297
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426
951 0.71 1.08 1.63
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0.90 1.15 1.47
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0.72 0.85 1.01
Lower
confidence
limit Estimate
Upper
confidence
limit
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870
426
951 0.70 1.32 2.48
0.69 1.73 4.37
1.07 1.91 3.42
0.75 1.53 3.10
1.12 5.04 22.73
1.13 1.62 2.31
Lower
confidence
limit Estimate
Upper
confidence
limit
Total
Maximum Hb < 10 g dl–1
< 11 g dl–1
< 12 g dl–1
12 – 13 g dl–1
> 13 g dl–1
Category Subgroup
Total
Maximum Hb < 10 g dl–1
< 11 g dl–1
< 12 g dl–1
12 – 13 g dl–1
> 13 g dl–1
Category Subgroup
Total
Maximum Hb < 10 g dl–1
< 11 g dl–1
< 12 g dl–1
12 – 13 g dl–1
> 13 g dl–1
0.2 0.4 0.6 1 2 3 456 10 20 30
Risk ratio
0.2 0.4 0.6 1 2 345 6 10 20 30
Risk ratio
0.2 0.4 0.6 1 2 3 456 10 20 30
Risk ratio
Figure 3 Subgroup analysis of hazard ratios for (A) overall survival, (B) time to progression and (C) time to TEE by maximum-achieved Hb level.
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sCONCLUSIONS
This individual patient data-based meta-analysis of 12 controlled
epoetin-b studies in cancer patients is the first to enable subgroup
analyses assessing the risk of ESA therapy associated with different
Hb-initiation levels. Results indicate that when used within the
terms of its licensed indication (i.e., Hb-initiation level p10gdl
 1)
or within the updated EORTC guidelines (i.e., Hb-initiation level
p11gdl
 1), there was no evidence of an increased risk of mortality
or disease progression associated with epoetin-b therapy. Consistent
with other published meta-analyses, the thromboembolic event rate
was significantly increased. The number and combination of
pre-disposing risk factors for TEEs at baseline should be taken
into account before initiating epoetin-b therapy, and potential
preventative measures should be considered. Although there is a
clear trend towards a higher risk of overall mortality, disease
progression and thromboembolic event rate was observed with
increasing baseline Hb values, such a trend was not seen in patients
who achieved higher Hb values, especially when Hb values above
13gdl
 1 were exceeded during therapy.
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